Skip to main content
FDA Shortage Check

Is Ativan (Lorazepam Injection) in shortage?

Label: plusbeauxjours · shortage label · not a prescription, not a pharmacy, not FDA

IN SHORTAGE

Ativan: in shortage (FDA, Oct 24)

Injections (vials)
A generic injection, not your medicine. We draw dosage forms, not products, and never pills you could match to yours.
  • Reason: “Demand increase for the drug”. FDA shortage reason (FDASIA), reported by the manufacturer
  • Reason: “Other”. FDA shortage reason (FDASIA), reported by the manufacturer
  • Estimate: “Estimated recovery: TBD”. Manufacturer’s estimate, Hikma Pharmaceuticals USA, Inc., Oct 14, 2026
DRUG
Ativan
FDA LISTING
FORM
injection
STATUS
Currently in Shortage
FIRST POSTED
May 3, 2018
LAST FDA UPDATE
Oct 21, 2026
AS OF
Oct 24, 2026
SOURCE

FDA lists 11 presentations: 4 unavailable · 5 limited · 2 available.

FDA Drug Shortages checked Oct 24, 2026, 21:05 ET · FDA updates daily · manufacturer-reported

Information from FDA’s drug shortage list, reported by manufacturers. Not medical advice. Don’t stop, change or ration a medicine without talking to your prescriber or pharmacist.

FDA's listing, word for word: Lorazepam Injection. 11 presentations from 4 makers.

Check your own medication, form and strength

What to ask at the counter

  1. Is this a supply problem at this pharmacy, or everywhere? Could another pharmacy have it? FDA consumer FAQ (opens in a new tab)
  2. Is my strength or the maker you stock affected? FDA list, by presentation
  3. Is there an alternative to this medicine I should ask my prescriber about? FDA consumer FAQ (opens in a new tab)
  4. When should I check back, or can you order it?

FDA: “talk with your health care provider or pharmacist for other treatment options during the shortage.” FDA Drug Shortages page (opens in a new tab)

This listing on FDA ↗ (opens in a new tab)Report a shortage to FDA: drugshortages@fda.hhs.gov

Every presentation FDA lists, by maker

Availability is FDA's text for each package, as the manufacturer reported it. Makers with unavailable or limited packages come first.

Hikma Pharmaceuticals USA, Inc.8 presentations · 4 unavailable · 4 limited

Contact (FDA's listing): 800-631-2174

  • 2 mg/1 mL

    Ativan, Injection, 2 mg/1 mL (NDC 0641-6000-10)

    Estimated recovery: TBD

    NDC 0641-6000-10Reverified

    Unavailable

  • 4 mg/1 mL

    Ativan, Injection, 4 mg/1 mL (NDC 0641-6002-10)

    Estimated recovery: TBD

    NDC 0641-6002-10Reverified

    Unavailable

  • 2 mg/1 mL

    Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6046-10)

    Estimated recovery: TBD

    NDC 0641-6046-10Reverified

    Unavailable

  • 4 mg/1 mL

    Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6047-10)

    Estimated recovery: TBD

    NDC 0641-6047-10Reverified

    Unavailable

  • 2 mg/1 mL

    Ativan, Injection, 2 mg/1 mL (NDC 0641-6001-25)

    Additional lots are scheduled to be manufactured. Product will be made available as it is released.

    NDC 0641-6001-25Revised

    Limited Availability

  • 4 mg/1 mL

    Ativan, Injection, 4 mg/1 mL (NDC 0641-6003-25)

    Additional lots are scheduled to be manufactured. Product will be made available as it is released.

    NDC 0641-6003-25Revised

    Limited Availability

  • 2 mg/1 mL

    Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6044-25)

    Additional lots are scheduled to be manufactured. Product will be made available as it is released.

    NDC 0641-6044-25Revised

    Limited Availability

  • 4 mg/1 mL

    Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6045-25)

    Additional lots are scheduled to be manufactured. Product will be made available as it is released.

    NDC 0641-6045-25Revised

    Limited Availability

Hospira, Inc., a Pfizer Company1 presentation · 1 limited

Contact (FDA's listing): 844-646-4398

  • 2 mg/1 mL Syringes

    Lorazepam, Injection, 2 mg/1 mL Syringes (NDC 0409-1985-30)

    Limited Supply Available. Next Delivery and Estimated Recovery: June 2027

    NDC 0409-1985-30Revised

    Limited Availability

Amphastar Pharmaceuticals, Inc.1 presentation · 1 available or not stated

Contact (FDA's listing): 800-423-4136

  • 2 mg/1 mL

    Lorazepam, Injection, 2 mg/1 mL (NDC 76329-8261-1)

    NDC 76329-8261-1Reverified

    Available

Fresenius Kabi USA, LLC1 presentation · 1 available or not stated

Contact (FDA's listing): 888-386-1300

  • 2 mg/1 mL

    Lorazepam, Injection, 2 mg/1 mL (NDC 65219-368-02)

    Check wholesalers for inventory

    NDC 65219-368-02Reverified

    Available

What the manufacturers told FDA

  • Hikma Pharmaceuticals USA, Inc. · ‘Estimated recovery: TBD’ · updated Oct 2026
  • Hospira, Inc., a Pfizer Company · ‘Limited Supply Available. Next Delivery and Estimated Recovery: June 2027’ · updated Oct 2026

More on FDA ↗ (opens in a new tab)

Reason for the shortage (FDASIA)

  • Demand increase for the drug
  • Other

As reported by the manufacturer under the Food and Drug Administration Safety and Innovation Act.

Alternatives

FDA lists none: “Providing a list of alternative drug products for a drug in shortage is part of the ‘practice of medicine.’ FDA does not regulate the practice of medicine.” Your prescriber or pharmacist can talk through options with you. ASHP also tracks shortages and suggested alternatives (different criteria) ↗ (opens in a new tab)

Questions

Is Ativan in shortage?
Yes. As of Oct 24, 2026, FDA lists Lorazepam Injection as currently in shortage: 11 presentations, 4 unavailable and 5 limited.
When will the Ativan shortage end?
FDA gives no end date. 5 presentations carry a manufacturer’s own estimate, quoted on this page with its date.
Does FDA list alternatives to Ativan?
No. FDA calls a list of alternatives part of the ‘practice of medicine’. Ask your pharmacist or prescriber.